Navigation Links
Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
Date:3/17/2008

Company's two lead ophthalmology programs in development are now funded by our partners."

Diabetic retinopathy (DR), a complication of diabetes mellitus, is the leading cause of blindness in the working-age population of developed countries. At any time during progression of diabetic retinopathy, patients can develop DME, which involves retinal thickening of the macular area. In the United States, as many as 200,000 people are diagnosed with DME each year and an estimated 1,000,000 people suffer from DME. Currently there are no FDA approved drug treatments for DME.

About Alimera Sciences Inc.

Alimera Sciences Inc. is singularly focused on the development and commercialization of prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patients' lives and strengthen physicians' ability to manage ocular conditions.

Alimera completed enrollment in October 2007 of its 956-patient Phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. Alimera has also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment for ophthalmic diseases. The agreement gives Alimera the exclusive option to license compounds which are NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera retains the right to use the Medidur delivery system for two of these compounds.

About pSivida Limited

pSivida is a global drug delivery company committed to the biomedical sect
'/>"/>

SOURCE Alimera Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
2. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
3. DARA BioSciences, Inc. Announces Appointment of New Director to Board
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Pressure BioSciences, Inc. Provides Corporate Update
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
(Date:5/27/2015)... 27, 2015 ­ Caris Life Sciences®, a ... precision medicine, today announced it has appointed the Levine ... of excellence site in the Caris Centers of Excellence ... Cancer Institute is one of the largest cancer care ... new cancer patients annually. Derek Raghavan , M.D., ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Regenestem ... new stem cells clinic in Buenos Aires, Argentina. The ... renowned critical care specialist. Pastrana has assembled a multidisciplinary ... and orthopedics in her state-of-the-art Puerto Madero office. ... phase I to phase IV clinical studies in cellular ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ... and solutions in the human and animal health ... annual Vetericyn® Future Innovators of Agriculture College Scholarship ... school senior who exhibits a passionate commitment to ... , This year’s winners, Alexis Pedrow from ...
Breaking Biology Technology:RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... , CRANBURY, N.J., Dec. 1 Palatin Technologies, Inc. ... U.S. Patent and Trademark Office has issued U.S. Patent ... claims in the issued patent cover a family of ... (NPRA), including PL-3994, Palatin,s lead heart failure drug candidate. ...
... , HUNTINGTON BEACH, ... molecular cancer diagnostics, announced today that,Palmetto GBA, California,s Part B ... MammaPrint is Agendia,s,FDA-cleared breast cancer recurrence test, which has been ... across the United States can now submit claims for the,MammaPrint ...
... , ... ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ... in the People,s Republic of China ("PRC"), today,announced that the ... ("MDK") to serve as its exclusive sales agent for the,Company,s ...
Cached Biology Technology:Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3
(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... the buzzword "nano" - cancer detection using nanoparticles and ... cancers is one of the most important parts of ... and determination,of the most appropriate treatment. And an essential ... there has been lymphatic spread. Current,methods include surgical removal ...
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... drugs that keep the HIV-virus infection from progressing to ... disturbances in some patients. The finding of a Mayo ... The Lancet. , In collaboration with colleagues from the ... University of Minnesota, Minneapolis, and University of Wisconsin, Madison, ...
Cached Biology News:Imaging Lymph Nodes with Nanoparticles 2GATA: a graphic alignment tool for comparative sequence analysis 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 3
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... Eagle's medium have been developed ... most widely used modification is ... a modification of Minimum Essential ... a higher concentration of vitamins ...
... Hollandes is a fixative useful for ... fixation. It is stable and will decalcify ... with Hollande's can be stained successfully with ... the solution stabilizes red blood cell membranes ...
... Gas Chromatograph/Mass Spectrometer, utilizing many of ... Plus, offers high throughput and excellent ... performance-to-cost ratio. Like the GCMS-QP2010 Plus, ... velocity for optimum separation, 20 temperature ...
Biology Products: